AVM Biotechnology

Great to see our Washington Competes winner Theresa Deisher of AVM Biotechnology at the National Institutes of Health Office of Extramural Research BIO booth. Suggest heading over to learn about how AVM Biotechnology is developing and advancing AVM0703, a proprietary formulation of concentrated dexamethasone. This formulation permits the very high dosing necessary to activate the release and trigger the production of the body’s supercharged gamma delta TCR+ invariant TCR+ bispecific T lymphocytes and Natural Killer T-like immune cells. These TCR bispecific immune cells have unique immune response properties in comparison to ordinary T-cells and rapidly appear following a single AVM0703 dose. Pre-clinical and clinical data indicate that these cells could play a significant role in several diseases and conditions.

Headed to #BIO2024? The NIH SEED is excited to sponsor 45 innovative, peer-reviewed companies with non-dilutive funding. Swing by the NIH booth (825) to learn more! AVM Biotechnology, Samy Hamdouche of Circumvent, Fabio Tucci of Epigen Biosciences, Inc., Jeff Liter Luminary Therapeutics, Inc, Dominique Lessard, Ph.D. of NeuCyte, Elena Molokanova, PhD of NeurANO Bioscience, Athan Kuliopulos of OASIS PHARMACEUTICALS LIMITED, Janak Padia of PRIMETIME LIFE SCIENCES, LLC, John Harkness, Ph.D. of Rewire AI, Jonathan Northrup of Stingray Therapeutics, Brian Kay of Tango Biosciences, Inc., Craig Ramirez, Ph.D. of Tezcat Biosciences, Samuel Chen of Truly Technologies, and David Mead of Terra Bioforge

📢 Latest Update 🔊 AVM Biotechnology is pleased to announce its participation in the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting in Chicago, IL from May 31st to June 4th, 2024. AVM Biotechnology is having 2 abstracts and 1 poster at the meeting: #ABSTRACTS 1. Durable complete response and overall survival in heavily pretreated, poor prognosis Non-Hodgkin’s Lymphoma to immunoactivating AVM0703 with few and mild drug-related adverse effects. 2.AVM0703 treatment overcomes the limitations of R-CHOP and improves survival in a model applicable to ABC subtype DLBCL #POSTER #7077 - Durable complete response and overall survival in heavily pretreated, poor prognosis Non-Hodgkin’s Lymphoma to immunoactivating AVM0703 with few and mild drug-related adverse effects (June 3rd, 9:00 AM – 12:00 PM) AVM Biotechnology has brought its lead drug, #AVM0703, from the most basic discovery research to Phase 2 clinical trials (no safety signal yet) and has established a very active, successful compassionate use/expanded access program. #AVM0703 is a unique proprietary formulation that activates a unique immune response “not targeted by any other available drug” by mobilizing gamma delta TCR invariant TCR double positive T lymphocytes and NKT-like cells and providing hope to DLBCL patients. If you are interested in learning more about how AVM0703 can change the cancer medicine field especially for “no option/frail patients”, or to support us in our mission (we are looking for additional partners/funds) please reach out to Theresa Deisher (Founder and CSO; tdeisher@avmbiotech.com), Dan Spina (Director; dspina@avmbiotech.com), Gerald McLean (Director; jmclean@avmbiotech.com) or Grant Atkins (grant@grantatkins.com). Excited to see you all in Chicago and please don’t forget to stop by our poster #7077 on June 3rd, 9-12 PM. #ASCO2024 #Immunotherapy #GammaDeltaNKTCells #Oncology #DLBCL #TLymphocytes

We’ve just updated our Page. Visit our Page to see the latest updates. AVM Biotechnology has been chosen by the National Institute of Health as a 2024 Innovation Company and will attend BIO 2024 June 3-6 as an NIH sponsored company. We hope to meet you there.

See a very compelling story of hope and loving life from one of the compassionate use patients being treated with AVM0703, published on page 3 in Allina Health's annual report. https://lnkd.in/gqmHHbtg